Published in Health and Medicine Week, May 18th, 2006
The influx of generic anxiety drugs will offset the revenue growth derived from existing drugs seeking additional anxiety indications, and the launch of several novel anxiety drugs, according to a research report, "Anxiety Disorders - A Decade of Declining Revenues," released by Research and Markets.
The reported includes an analysis for key products in development for GAD (generalized anxiety disorder), SAD (social anxiety disorder), OCD (obsessive-compulsive...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week